# Title
Effect O
of O
CYP3A5 B-Gene
polymorphism O
on O
tacrolimus B-Chemical
metabolic O
clearance O
in O
vitro. O

# Abstract
Previous O
investigations O
of O
solid O
organ O
transplant O
patients B-Species
treated O
with O
tacrolimus B-Chemical
showed O
that O
individuals O
carrying O
a O
CYP3A5*1 O
allele O
have O
lower O
dose-adjusted O
trough O
blood O
concentrations O
compared O
with O
homozygous O
CYP3A5*3 O
individuals. O
The O
objective O
of O
this O
investigation O
was O
to O
quantify O
the O
contribution O
of O
CYP3A5 B-Gene
to O
the O
hepatic O
and O
renal O
metabolic O
clearance O
of O
tacrolimus. B-Chemical
Four O
primary O
tacrolimus B-Chemical
metabolites, O
13-O-desmethyl B-Chemical
tacrolimus B-Chemical
(13-DMT) B-Chemical
(major), O
15-O-desmethyl B-Chemical
tacrolimus, B-Chemical
31-O-desmethyl B-Chemical
tacrolimus B-Chemical
(31-DMT), B-Chemical
and O
12-hydroxy B-Chemical
tacrolimus B-Chemical
(12-HT), B-Chemical
were O
generated O
by O
human B-Species
liver O
microsomes O
and O
heterologously O
expressed O
CYP3A4 B-Gene
and O
CYP3A5. B-Gene
The O
unbound O
tacrolimus B-Chemical
concentration O
was O
low O
(4-15%) O
under O
all O
incubation O
conditions. O
For O
CYP3A4 B-Gene
and O
CYP3A5, B-Gene
V(max) O
was O
8.0 O
and O
17.0 O
nmol O
min O
nmol O
enzyme O
and O
K(m,u) O
was O
0.21 O
and O
0.21 O
muM, O
respectively. O
The O
intrinsic O
clearance O
of O
CYP3A5 B-Gene
was O
twice O
that O
of O
CYP3A4. B-Gene
The O
formation O
rates O
of O
13-DMT, B-Chemical
31-DMT, B-Chemical
and O
12-HT B-Chemical
were O
>or=1.7-fold O
higher, O
on O
average, O
in O
human B-Species
liver O
microsomes O
with O
a O
CYP3A5*1 O
*3 O
genotype O
compared O
with O
those O
with O
a O
homozygous O
CYP3A5*3 O
*3 O
genotype. O
Tacrolimus B-Chemical
disappearance O
clearances O
were O
15.9 O
+ O
- O
9.8 O
ml O
min O
mg O
protein O
and O
6.1 O
+ O
- O
3.6 O
ml O
min O
mg O
protein, O
respectively, O
for O
the O
two O
genotypes. O
In O
vitro O
to O
in O
vivo O
scaling O
using O
both O
liver O
microsomes O
and O
recombinant O
enzymes O
yielded O
higher O
predicted O
in O
vivo O
tacrolimus B-Chemical
clearances O
for O
patients B-Species
with O
a O
CYP3A5*1 O
*3 O
genotype O
compared O
with O
those O
with O
a O
CYP3A5*3 O
*3 O
genotype. O
In O
addition, O
formation O
of O
13-DMT B-Chemical
was O
13.5-fold O
higher O
in O
human B-Species
kidney O
microsomes O
with O
a O
CYP3A5*1 O
*3 O
genotype O
compared O
with O
those O
with O
a O
CYP3A5*3 O
*3 O
genotype. O
These O
data O
suggest O
that O
CYP3A5 B-Gene
contributes O
significantly O
to O
the O
metabolic O
clearance O
of O
tacrolimus B-Chemical
in O
the O
liver O
and O
kidney. O